BioMarin Pharmaceutical | BMRN - 销售收入



金融业
股票价格
USD 56.04
资产
USD 11.72B
现金及等价物
USD 874.01M
销售成本
USD 276.29M
流动资产
USD 3.97B
流动负债
USD 1.66B
债务
USD 1.44B
EBIT
USD 105.61M
EBITDA
USD 146.05M
员工
3.04K
EPS每股收益
USD 1.2
股本和储备
USD 6.32B
销售毛利
USD 713.42M
债务利息支出
USD 63.3M
利息收入
USD 22.56M
贷款资金
USD 3.53B
市值
USD 10.9B
净收入
USD 44.76M
营业费用
USD 6.32B
营业利润
USD 105.61M
普通股股本
USD 193.54M
PE价格收益
21.07
税前利润
USD 141.2M
销售收入
USD 990M
销售和管理费用
USD 395.55M
股票
USD 1.78B
贸易债权人
USD 913.67M
应收帐款人
USD 1.06B


销售 更改 日
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Amgen USD 10.1B 1.48B 2026-06
Bayer EUR 10.87B 2.54B 2026-06
Biogen USD 2.74B 490M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Gilead Sciences USD 7.8B 800M 2026-06
Incyte USD 1.67B 400M 2026-06
Insmed USD 425.49M 119.53M 2026-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
Moderna USD 100M 289M 2026-06
Neurocrine Biosciences USD 959M 148M 2026-06
PTC Therapeutics USD 361M 88M 2026-06
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Roche Holding CHF 30.36B 14.71B 2026-06
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 12.14B 65M 2026-03
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
United Therapeutics USD 783.3M 1.8M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06